Fig. 1 · Structure

Documents & Downloads

Andrographolide

Cat. No. A10077 CAS 5508-58-7

Apoptosis Inducer

Andrographolide is an interesting pharmacophore with anticancer and immunomodulatory activities and hence has the potential for being developed as a cancer therapeutic agent.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Andrographolide covalently modifies Cys62 of NF-κB p50: a parent-compound LC-MS/MS experiment identified the modified peptide. This target-engagement result does not establish selective inhibition or an IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
NF-κB

Cellular Effect

Cell Line Activity Value Description Reference
A2058 IC50 26 μM Cytotoxicity against human A2058 cells incubated for 48 hrs by MTT assay [PMID: 33289552]
A549 IC50 12.15 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay [PMID: 33316411]
A549 GI50 13.37 μM Growth inhibition of human A549 cells after 72 hrs by SRB assay [PMID: 23768904]
A549 IC50 27.9 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay [PMID: 28755636]
A549 IC50 32.02 μM Anticancer activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay [PMID: 32527561]
A549 IC50 9.71 μg/mL Cytotoxicity against human A549 cells by MTT assay 10.1039/C4MD00566J
ACHN IC50 3.03 μg/mL Cytotoxicity against human ACHN cells by MTT assay 10.1039/C4MD00566J
B16 IC50 7.54 μg/mL Cytotoxicity against mouse B16 cells by MTT assay 10.1039/C4MD00566J
BMDM IC50 0.55 μM Inhibition of GST-tagged recombinant RANKL/M-CSF-induced osteoclastogenesis in C57BL/6 mouse bone marrow derived macrophages assessed as TRAcP enzymatic activity incubated for 5 days with subsequent replenishment of media for 2 days and measured by leucoc [PMID: 33158578]
BMMC IC50 1.01 μM Anti-osteoporosis activity in C57BL/6 mouse BMM cells assessed as inhibition of M-CSF/RANKL-induced osteoclastogenesis by measuring reduction in multinucleated TRAP+ cells incubated for 5 days with media replenishment for every 48 hrs measured by TRAP-sta [PMID: 33485256]
BMMC CC50 10.31 μM Cytotoxicity against C57BL/6 mouse BMM cells assessed as reduction in cell viability measured after 48 hrs in presence of M-CSF by CCK8 assay [PMID: 33485256]
Col2 ED50 13.6 μM Cytotoxicity against human Col2 cells by SRB assay [PMID: 22154665]
DU-145 GI50 15.99 μM Growth inhibition of human DU145 cells after 72 hrs by SRB assay [PMID: 23768904]
HCT-116 IC50 23.93 μM Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay [PMID: 23628335]
HCT-116 IC50 31.8 μM Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay [PMID: 34315039]
HCT-116 GI50 4.5 μM Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition measured after 96 hrs by MTT assay [PMID: 33228976]
HEK293 CC50 26.25 μM Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 24 hrs by Celltiter-glo assay [PMID: 32712435]
HEK293 IC50 49.6 μM Inhibition of TNF-alpha-stimulated NF-kappaB p50 (unknown origin) expressed in HEK293 cells preincubated for 4 hrs followed by TNF-alpha challenge measured after 24 hrs by secreted alkaline phosphatase reporter assay [PMID: 25615020]
HeLa IC50 10.42 μg/mL Cytotoxicity against human HeLa cells by MTT assay 10.1039/C4MD00566J
HeLa IC50 23 μM Antiviral activity against DENV2 infected in human HeLa cells incubated for 1 hrs by plaque assay [PMID: 34315039]

20 records · Scroll to view more

Andrographolide Research Summary

This section summarizes 2 in vitro studies of Andrographolide from 1 published reference.

Andrographolide In Vitro Studies

Andrographolide reduced HCT116 cell migration and invasion at 5 μM over 30 h. These in vitro observations should not be equated with demonstrated antimetastatic efficacy in vivo. [1]

Covalent modification of recombinant NF-κB p50

Biochemical assay · Recombinant NF-κB p50 protein; parent compound versus DMSO control [1]

LC-MS/MS identified an andrographolide-modified Cys62-containing peptide. This supports direct covalent target engagement, without establishing a binding constant or target selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Modification of the Cys62-containing p50 peptideAdduct mass increment +332.2 Da[1]

Literature-Reported Treatment Conditions

Treatment concentration
As reported: 1 μL of 10 mM andrographolide stock with 50 μg p50 in 100 μL PBS.
Exposure duration
4 h at room temperature
Method
Incubation with recombinant protein before LC-MS/MS mapping
Vehicle
DMSO control; final solvent percentage not explicitly given for this experiment.
Reported limits
Replicate count and uncertainty of adduct detection not specified in the selected text; no affinity or inhibitory-potency measurement in this experiment.
Methods and source locations

Compound reported in the paper: Andrographolide; Compound label in the paper: Andro

Published parent-compound evidence; does not validate Adooq material, the reduced analogue or clickable probes.

Experimental Procedures, p50 binding-site mapping by MS/MS; Materials and Reagents; Figs. 2 and 5D; Target Validation and Functional Analysis

Modification of the Cys62-containing p50 peptide: LC-MS/MS after parent-compound incubation and tryptic digestion — Fig. 5D, mass-shift annotation; Target Validation and Functional Analysis, parent p50 MS/MS paragraph

HCT116 migration and invasion

Cell-based study · Human HCT116 colorectal cancer cells; DMSO and reduced analogue RA comparator groups [1]

At 5 μM for 30 h, andrographolide reduced migration through fibronectin-coated inserts and invasion through Matrigel-coated inserts relative to DMSO. These cellular endpoints do not demonstrate reduced metastasis in animals.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Migration toward serum-containing mediumDirectional effect Reduced; Fig. 7B marks *** p < 0.001[1]
Invasion through MatrigelDirectional effect Reduced; Fig. 7C marks *** p < 0.001[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
30 h
Method
Exposure during migration/invasion assays
Vehicle
1% DMSO negative control explicitly stated for migration; Fig. 7 also labels a DMSO invasion control, without a separately specified solvent percentage.
Co-treatment
None; RA (5 μM) was a separate comparator.
Reported limits
Biological replicate number, error-bar definition and statistical test for Fig. 7 are not specified in the selected methods/legend. No numerical bar heights inferred. The authors describe 5 μM as noncytotoxic, but a matched 30 h viability control was not independently verified.
Methods and source locations

Compound reported in the paper: Andrographolide; Compound label in the paper: Andro

Published parent-compound evidence; does not validate Adooq material, the reduced analogue or clickable probes.

Materials and Reagents; Transwell Migration Assay; Matrigel Invasion Assay; Target Validation and Functional Analysis, migration/invasion paragraph; Fig. 7A–C

Migration toward serum-containing medium: Transwell migration, crystal-violet signal at 550 nm — Transwell Migration Assay; Fig. 7A–B and legend

Invasion through Matrigel: Cells counted in five randomly selected microscopy fields — Matrigel Invasion Assay; Fig. 7A,C and legend

Specifications

Manufacturer Adooq Bioscience
Actions Inducer
CAS Number 5508-58-7
Applications Apoptosis Inducer
Formula C20H30O5
Molecular Weight 350.5
SMILES
C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2C/C=C/3\[C@@H](COC3=O)O)(C)CO)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 65 mg/mL (185.47 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Andrographolide Research References

  1. [1] Wang J, Tan XF, Nguyen VS, et al. A quantitative chemical proteomics approach to profile the specific cellular targets of andrographolide, a promising anticancer agent that suppresses tumor metastasis. Molecular & cellular proteomics : MCP (2014). PMID: 24445406 DOI: 10.1074/mcp.m113.029793 Source material

Added to your cart

View Cart Checkout
Loading...